Thus, the combination of foretinib, a potent MET and AXL inhibitor, with erlotinib therapy in NSCLC appears a rational and promising way to exploit potential synergism between agents and to overcome primary resistance as well as delaying the development of resistance to EGFR kinase therapy. Here, AXL is linked to non-small cell lung carcinoma.